Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

The Safety Review Committee approved enrollment of the next higher-dose cohorts as follows: Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV ...